C. Ottensmeier, et al. ASCO 2023 Abstract available on the ASCO website – Download the abstract and the posterPoster Presentation
Category: 2023
Immunogenicity and clinical activity of Tipapkinogen sovacivec (TG4001), an HPV-16 cancer vaccine: a randomized phase 2 study in recurrent or metastatic (R/M) anogenital cancers
Transgene to Present Data on its Two Therapeutic Cancer Vaccins at the 2023 American Society of Clinical Oncology (ASCO) Annual Meeting
Transgene to present data on its two therapeutic cancer vaccines at the 2023 ASCO annual meeting
Transgene and BioInvent report positive Phase Ia data on oncolytic virus BT-001 in solid tumors
Transgene and BioInvent report positive Phase Ia data on oncolytic virus BT-001
Transgene provides business update and Q1 2023 financial position
business update and Q1 2023 financial position 15
Transgene – First Patient Dosed in Phase I Trial Evaluating TG6050, a Novel IL-12-Armed Oncolytic Virus Administrated Intravenously, in Non-Small Cell Lung Cancer
First patient dosed in Phase I trial evaluating TG6050 15
Transgene’s Combined General Meeting of May 5, 2023
Transgene’s combined general meeting 15
Transgene Announces New Leadership Structure to Accelerate the Development of its Innovative Immunotherapy Portfolio
Transgene Announces New Leadership Structure to Accelerate the Development of its Innovative Immunotherapy Portfolio 15
Advanced patient-derived lung tumoroids to identify limiting factors for oncolytic virotherapy
H. Le et al.AACR 2023Download the poster herePoster Presentation
PoxSTG, a novel chimeric poxvirus with improved oncolytic potency
P Erbs et al.AACR 2023Download the poster herePoster Presentation
